Media headlines about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.1095246549132 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Akebia Therapeutics (AKBA) opened at $15.05 on Monday. Akebia Therapeutics has a fifty-two week low of $8.09 and a fifty-two week high of $20.25.
Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The business had revenue of $41.28 million during the quarter, compared to analyst estimates of $34.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. equities research analysts forecast that Akebia Therapeutics will post -2.25 earnings per share for the current fiscal year.
Several research analysts have recently commented on the stock. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank of Canada assumed coverage on shares of Akebia Therapeutics in a report on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 price target for the company. Mizuho assumed coverage on shares of Akebia Therapeutics in a report on Wednesday, October 4th. They issued a “buy” rating and a $24.00 price target for the company. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $21.78.
In other Akebia Therapeutics news, SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $19.64, for a total transaction of $27,456.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 7,586 shares of company stock valued at $147,289 over the last three months. 7.95% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This news story was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.truebluetribune.com/2017/12/18/akebia-therapeutics-akba-given-coverage-optimism-score-of-0-10.html.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.